相关实验视频

Updated: Jul 17, 2025

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray

Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray

Published on: April 25, 2014

在Mycobacterium tuberculosis中,自发突变模式和贝达奎林和克洛法齐明抗性的新突变

Jin Shi¹, Yuanyuan Liu², Tuoya Wu³

¹Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute , Beijing, China.

Microbiology spectrum

|August 30, 2023

概括

新的研究揭示了Mycobacterium tuberculosis (MTB) 中明显的基因突变模式,使其对关键的结核病药物贝达奎林和克洛法齐明产生抗药性. 了解这些耐药性机制对于有效的治疗策略至关重要.

科学领域:

微生物学与传染病的研究
遗传学和分子生物学
药物耐药性机制药物耐药性机制

背景情况:

世界卫生组织的指导方针推贝达基林 (BDQ) 和克洛法齐明 (CFZ) 治疗耐药结核病 (DR-TB).
在Mycobacterium tuberculosis (MTB) 中的零星突变赋予对BDQ和CFZ的耐药性尚未完全表征.
了解获得性耐药性对于优化DR-TB治疗至关重要.

研究的目的:

描述MTB中的自发突变,使其对BDQ和CFZ产生抗性.
调查这些突变对MmpR和PepQ蛋白质功能的影响.
为了阐明BDQ和CFZ抵抗之间的突变模式的差异.

主要方法:

从耐药性,多耐药性和广泛耐药性结核病患者的临床MTB分离物进行培养.
隔离物被*体外*暴露在BDQ或CFZ中以产生耐药后代菌株.
确定了最小抑制度 (MIC),并确定和分析了自发基因突变 (mmpR,pepQ).

主要成果:

与BDQ暴露后代相比,暴露于CFZ后代的MIC增加率较高.
*mmpR* (83%BDQ,86%CFZ) 和*pepQ* (17%BDQ,14%CFZ) 的突变是抵抗的主要驱动因素.
在MmpR和PepQ的点突变影响了蛋白质序列和功能,解释了获得的耐药性.

结论:

自发突变的独特模式在MTB中赋予了对BDQ和CFZ的获得性耐药性.
蛋白质序列和结构分析为突变-表型关联提供了洞察力.
这些发现为MTB BDQ/CFZ抵抗机制提供了新的视角,有助于诊断的发展.

关键词:

结核病菌菌菌的结核病菌的结核病菌.贝达奎林贝达奎林是一种克洛法齐米因 (Clofazimine) 是一种类药物.电阻的电阻是指电阻的电阻

更多相关视频

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples

Published on: June 6, 2025

相关概念视频

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Development of Antibiotic Resistance

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...